In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Kestra Medical Technologies Ltd (NASDAQ: KMTS) closed at $186.31K up 1312305% from its previous closing price of $15.51. In other words, the price has increased by $1312305 from its previous closing price. On the day, 1.31 million shares were traded.
Ratios:
For a deeper understanding of Kestra Medical Technologies Ltd’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.65 and its Current Ratio is at 1.81. In the meantime, Its Debt-to-Equity ratio is 7.22 whereas as Long-Term Debt/Eq ratio is at 7.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on March 31, 2025, initiated with a Outperform rating and assigned the stock a target price of $29.
On March 31, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $28.
On March 31, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $28.Stifel initiated its Buy rating on March 31, 2025, with a $28 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KMTS now has a Market Capitalization of 771770944. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.66.
Stock Price History:
Over the past 52 weeks, KMTS has reached a high of $26.15, while it has fallen to a 52-week low of $14.15. The 50-Day Moving Average of the stock is -32.17%, while the 200-Day Moving Average is calculated to be -33.15%.
Shares Statistics:
A total of 51.35M shares are outstanding, with a floating share count of 15.66M. Insiders hold about 69.51% of the company’s shares, while institutions hold 26.28% stake in the company.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The firm’s stock currently is rated by 5 analysts. The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.45 and low estimates of -$0.52.
Analysts are recommending an EPS of between -$1.73 and -$3.51 for the fiscal current year, implying an average EPS of -$2.2. EPS for the following year is -$1.89, with 5.0 analysts recommending between -$1.68 and -$2.02.
Revenue Estimates
For the next quarter, 6 analysts are estimating revenue of $17.53M. There is a high estimate of $17.9M for the next quarter, whereas the lowest estimate is $17.33M.
Based on 6 analysts’ estimates, the company’s revenue will be $82.91M in the next fiscal year. The high estimate is $83.8M and the low estimate is $82.26M.
